UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 4, 2016

 

 

IDEXX LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-19271   01-0393723

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

One IDEXX Drive, Westbrook, Maine   04092
(Address of principal executive offices)   (ZIP Code)

207.556.0300

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 4, 2016, IDEXX Laboratories, Inc. (the “Company”) held its 2016 annual meeting of stockholders (the “Annual Meeting”), at which a quorum was present in person or by proxy.

At the Annual Meeting, stockholders considered and voted on the following proposals, each of which is described in more detail in the Company’s proxy statement dated March 24, 2016, (the “Proxy Statement”): (1) the election of three Class III directors for terms expiring at the 2019 annual meeting of stockholders; (2) the ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered accounting firm for the current fiscal year; and (3) the approval, on an advisory basis, of the compensation of the Company’s named executive officers as presented in the Company’s proxy statement delivered to stockholders in connection with the Annual Meeting.

The voting results at the Annual Meeting with respect to each of the matters described above, were as follows:

Proposal One: Election of Directors

 

Nominees

   For      Against      Abstain      Broker Non-Votes  

Jonathan W. Ayers

     70,827,823         867,309         25,675         10,898,243   

Barry C. Johnson, PhD

     71,506,945         180,387         33,475         10,898,243   

M. Anne Szostak

     69,857,703         1,831,097         32,007         10,898,243   

Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm

 

For

     82,208,121   

Against

     380,483   

Abstain

     30,446   

Broker Non-Votes

     0   

Proposal Three: Advisory Vote to Approve Executive Compensation

 

For

     70,918,311   

Against

     643,978   

Abstain

     167,518   

Broker Non-Votes

     10,898,243   

 

1


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

            IDEXX LABORATORIES, INC .

Date: May 6, 2016

    By:  

/s/ Jacqueline L. Studer

      Jacqueline L. Studer
      Corporate Vice President, General Counsel and Secretary

 

2

IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more IDEXX Laboratories Charts.
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more IDEXX Laboratories Charts.